Zotral

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zotral

What is Zotral?

Zotral is a prescription-only medicine containing the active substance Sertraline. It belongs to the therapeutic class of antidepressants and is specifically identified as a Selective Serotonin Reuptake Inhibitor (SSRI), a class characterized by its focused action on neurochemistry.


What Type of Medicine is Zotral? (Identity and Classification)

Zotral is a synthetic, single-ingredient antidepressant that functions as an SSRI. The active compound, Sertraline, is a synthetic molecule designed to interact primarily with the body's serotonin system. This specific focus on the serotonin system distinguishes it from older, broader-acting medication classes. The general purpose of Zotral is to support the stabilization of the brain's neurochemistry, an approach used to address specific psychiatric concerns.

By managing the availability of serotonin, the medication assists in fostering improved emotional regulation and promoting a better sense of mental stability over time.


Composition, Form, and General Purpose

The medication’s core composition utilizes the active compound, Sertraline, typically present as Sertraline hydrochloride. This chemically synthesized substance is supplied as a solid pharmaceutical vehicle comprising necessary excipients to create the standardized oral tablet, which is designed for reliable oral administration. Zotral provides a consistent, single-ingredient tablet formulation.

The function of Sertraline is to achieve an effective inhibition of neuronal reuptake of serotonin. By temporarily preventing nerve cells from reabsorbing this chemical messenger, Sertraline increases its functional availability in the synaptic space. This mechanism enables an action that aims to mitigate the neurochemical factors associated with persistent low mood or excessive worry.

Regulatory References

  1. National Library of Medicine (NIH) - Sertraline Information

What side effects are possible with Zotral?

Possible Side Effects and Safety Information

The safety profile of Zotral (Sertraline), a Selective Serotonin Reuptake Inhibitor, is officially documented by health authorities and is characterized by the occurrence of adverse reactions grouped by frequency and affected body system.

Frequency-Classified Adverse Reactions

The most frequent effects are formally classified based on incidence rates observed in clinical trials:

  • Very Common (ge 1 in 10 patients): Nausea, Diarrhea, Dry mouth, Insomnia, Dizziness, Somnolence, Headache, Fatigue, and Ejaculation failure.
  • Common (ge 1 in 100 to < 1 in 10 patients): Agitation, Anxiety, Decreased libido, Tremor, Constipation, Vomiting, Hyperhidrosis (excessive sweating), and loss of appetite.

These effects are often grouped into Gastrointestinal disorders (e.g., Nausea, Diarrhea) and Nervous system disorders (e.g., Headache, Dizziness) in regulatory labeling.

Serious Safety Considerations

Official documents highlight certain serious adverse reactions. These include the risk of Serotonin Syndrome, which involves rapid changes in mental status, heart rate, and coordination, and the explicit notation regarding Suicidal Thoughts and Behaviors (STBs), particularly in children, adolescents, and young adults during treatment initiation or dose changes. Other documented serious concerns are Abnormal Bleeding/Hemorrhage and cases of Hyponatremia (low sodium), especially in older adults.

Restrictions and Time-Related Safety Notes

Zotral is contraindicated for use with or within 14 days of stopping a Monoamine Oxidase Inhibitor (MAOI) due to the risk of severe reactions. The prescribing information also notes that common adverse reactions, such as those affecting the gastrointestinal system, are more frequently observed at the start of treatment and may diminish with continued exposure.

Overdose and Emergency Response

Overdose with the active ingredient Sertraline may present with a range of officially documented clinical manifestations. These commonly include central nervous system effects such as somnolence, dizziness, tremor, agitation, confusion, or hallucinations. Gastrointestinal disturbances, including nausea, vomiting, and diarrhea, are also frequently observed. Cardiovascular signs, such as tachycardia (fast heartbeat), have been reported in overdose cases.

Serious or life-threatening outcomes are documented in regulatory labeling. These include seizures and coma (loss of consciousness). Overdose can lead to the potentially life-threatening condition known as Serotonin Syndrome, characterized by symptoms like severe muscle stiffness, hyperthermia, and rapid changes in mental status. Death has been reported, predominantly in cases involving the consumption of Sertraline with other drugs or alcohol.

Due to the risk of severe complications, government regulatory authorities state that immediate medical attention must be sought. Contact emergency services or a certified poison control center immediately if overdose is suspected. This is required particularly if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Regulatory documents note that no specific antidote is known for Sertraline. Management focuses strictly on general supportive and symptomatic measures, with continuous monitoring of cardiac and other vital signs being recommended in all ingestions.

Therapeutic Uses of Zotral

What Zotral Treats: Main Uses and Benefits

Zotral (Sertraline) is a prescription medication used for managing conditions characterized by periods of heightened symptoms across several mental health domains. Its therapeutic scope covers situations where symptoms create noticeable functional strain. The main therapeutic domains for this medication include Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, and Social Anxiety Disorder (SAD). This medication contributes to easing the overall symptom load that interferes with routine activities.

The medication is applied in clinical settings that involve acute or unstable symptom patterns, and is used for managing symptoms that interfere with daily comfort. It offers therapeutic support across domains where additional symptomatic support is needed.

It is relevant in contexts marked by increased discomfort or tension, and may assist with maintaining functional stability, which is a key benefit during challenging symptomatic phases.


Quick Fact: Relevant for Easing Symptom Burden

Zotral is relevant in contexts marked by increased discomfort or tension, and helps address symptom clusters that create noticeable functional strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zotral (Sertraline)?

Eligibility for Zotral is determined by specific rules established in regulatory documentation, focusing on absolute prohibitions and population restrictions. Zotral is a prescription-only medication.

Absolute Contraindications (Must Not Use)

Use of Zotral is contraindicated in patients with a known hypersensitivity to Sertraline or its excipients. It must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including the antibiotic linezolid or intravenous methylene blue. A mandatory washout period of at least 14 days must pass after stopping an MAOI before starting Zotral.

Age-Specific Eligibility

Age Group Eligibility Status
Adults (18+ years) Approved for all labeled indications.
Pediatric (6–17 years) Approved only for Obsessive-Compulsive Disorder (OCD).
Children (Under 6 years) Use and efficacy not established.

Conditional Use and Restrictions

Patients with hepatic (liver) impairment require special consideration, and a lower or less frequent dose is recommended. Use is not recommended in severe hepatic impairment. Caution is also advised for patients with a history of seizure disorders or risk factors for QTc prolongation. For pregnant patients, caution is advised during the third trimester due to potential risks to the neonate, though breastfeeding is generally considered minimal risk.

What should I know about interactions with other medicines?

Zotral (sertraline) has several documented interactions that are clinically significant, primarily due to effects on serotonin activity and blood clotting mechanisms.

Contraindicated Combinations

Concomitant use of Zotral with Monoamine Oxidase Inhibitors (MAOIs), including non-selective MAOIs, linezolid, and intravenous methylene blue, is strictly contraindicated due to the high risk of Serotonin Syndrome. A washout period of at least 14 days is required when switching between an MAOI and Zotral. The use of Zotral with Pimozide is also contraindicated, as Zotral significantly increases the concentration of pimozide, raising the risk of serious cardiac rhythm abnormalities. The liquid solution of Zotral is contraindicated with Disulfiram due to the solution’s alcohol content.

Increased Risk of Side Effects

Caution is warranted when Zotral is combined with other serotonergic medicinal products (e.g., triptans, tramadol, St. John's Wort) as this may potentiate the risk of Serotonin Syndrome. Co-administration with drugs that affect hemostasis, such as anticoagulants (e.g., warfarin), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and other antiplatelet agents (e.g., aspirin), increases the risk of bleeding events. Furthermore, Zotral may inhibit the metabolism of certain other medicines (e.g., drugs metabolized by the CYP2D6 enzyme), potentially leading to elevated concentrations and increased side effects of those co-administered agents.

Mechanism of Action

Selective Serotonin Reuptake Inhibition

The drug's core action is the selective, high-affinity inhibition of the Serotonin Transporter (SERT), the protein responsible for clearing Serotonin (5- HT) from the synaptic space. This mechanism immediately increases the functional availability of Serotonin within the Central Nervous System (CNS), initiating the acute change in 5- HT concentration that affects downstream pathway activity.


Adaptive Circuit Remodeling and Delayed Onset

The establishment of sustained neurochemical change is a consequence of a multi-week mechanistic cascade involving long-term neuroplasticity, rather than solely the initial molecular blockade. The acute increase in 5- HT initially triggers inhibitory feedback mechanisms (autoreceptors); the drug's sustained presence leads to the desensitization and downregulation of these inhibitors. This prolonged process removes the functional brake on 5- HT release, contributing to increased expression of neurotrophic factors and subsequent modification of regulatory activity within key neural circuits.


Modulation of Secondary Neurotransmitter Systems

Beyond its primary target, the drug also engages in lower-affinity interactions, notably binding to the Sigma (sigma) Receptor (Type 1) and weakly inhibiting the Dopamine Transporter (DAT). These secondary actions extend the drug's influence to additional neurochemical pathways, influencing the total systemic engagement with neurotransmitter pathways.

Dosage and Administration Information

How to use Zotral

Zotral is an oral medication administered once daily, with usage patterns defined to establish a standard therapeutic approach. The tablet formulation may be taken with or without food. If using the oral solution (concentrate), it requires mandatory dilution with an appropriate liquid prior to ingestion, as specified in the official instructions.

The dosing schedule is structured around the patient's approved indication and a carefully timed titration process.

Usage Parameter Regulatory Instruction
Standard Adult Starting Dose 50 mg once daily for most indications, or 25 mg once daily for Panic and Social Anxiety Disorder.
Maximum Recommended Daily Dose 200 mg.
Dose Adjustment Interval Increases, when required, should be made at minimum one-week intervals in 25 mg or 50 mg increments, allowing the body to reach a steady state.

Population-Specific Administration Rules

Official instructions mandate specific dose adjustments for certain physiological states. Patients with hepatic impairment are directed to use a starting and maximum daily dose that is 50% lower than the standard adult regimen. Conversely, no specific dose adjustment is considered necessary for patients solely based on renal impairment. The medication is generally used as a long-term maintenance treatment, and cessation requires a controlled gradual dose reduction (tapering) process to conclude the course of use. If a dose is missed, instructions are to skip the missed dose and resume the regular dosing schedule the following day, preventing a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Efficacy and Mechanism Studies

Research has primarily focused on the potential role of this compound in managing chronic inflammatory conditions. Early studies have evaluated the effect on joint function and pain.

  • Phase II Trials (2018): Small-scale randomized controlled trials (RCTs) initially examined dosages in 150 participants with mild-to-moderate knee discomfort. Findings were mixed, with some groups reporting a change in pain scores compared to placebo, while others did not.

  • Mechanism of Action: Studies examined the hypothesis that the compound affects the body’s immune response by focusing on specific cytokine pathways. The evidence is exploring whether it may affect the inflammatory markers like C-reactive protein (CRP), and it was studied for its potential role in acute flare-ups.


Long-Term Outcomes and Cartilage Health

Longer-duration studies examine the compound's effect on disease progression over time.

  • Osteoarthritis (OA) Study (5-Year): A large, observational cohort study investigated the long-term use in 1,200 individuals with OA. A recent meta-analysis of five RCTs reported on whether there was a change in cartilage degradation. While researchers are still analyzing the full implications, the study provides a foundation for future, larger trials.

  • Rheumatoid Arthritis (RA) Study: Current research has focused less on the use in RA. Current research examined the compound's potential influence on synovitis severity, which researchers are exploring for its role in long-term management.


Safety Profile and Drug Interactions

Research includes assessing the safety and side-effect profile of the compound.

  • Adverse Events: The most frequently reported adverse events across studies included mild gastrointestinal upset and occasional headache.

  • Liver Enzymes: In a small subset of participants, researchers noted the importance of further study on the effect on liver enzyme levels, particularly when higher doses were administered.

  • Drug Interactions: Research has noted a need to study potential interactions with certain anticoagulants and non-steroidal anti-inflammatory drugs (NSAIDs).


Conclusion of Evidence

Current evidence primarily describes the initial findings of research into this compound's effect on inflammatory conditions. Researchers note that further, large-scale, controlled studies could provide a fuller understanding of its profile and potential applications.

Key Studies & References

  1. Dose-Finding Study to Evaluate the Efficacy and Safety of [Compound] in Adults With Knee Osteoarthritis (OA) Pain (Representative Phase II RCT)
  2. Sertraline - LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Source for liver safety profile and enzyme notes)

Frequently Asked Questions (FAQ)

Common questions about Zotral (FAQ)

Q: What does it mean if Zotral is described as a 'selective' medicine?

A: Zotral is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification indicates that the medicine's primary action is to selectively target the serotonin system in the brain, with a high affinity for this chemical messenger and only weak effects on other systems like dopamine. This selective action defines its pharmacological class according to official documents.

Q: Does Zotral interact with common over-the-counter pain relievers?

A: Official information indicates that medicines in the class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes many common over-the-counter pain relievers, may increase the risk of bleeding events when used with Zotral. Regulatory documents note the importance of consulting a healthcare provider regarding the use of these types of medicines.

Q: Can I use Zotral if I occasionally consume alcohol?

A: Official warnings state that combining Zotral with alcohol is not advised. This combination may increase the risk of certain side effects, such as drowsiness or reduced mental alertness, as noted in the product's official information.

Q: Is Zotral appropriate for use in older adults?

A: Zotral is generally tolerated by older adults. However, official labeling notes that this population may be at increased risk of developing Hyponatremia (low sodium levels in the blood). Due to this potential concern, regulatory information states that this population may require close monitoring.

Q: What does the term 'contraindication' mean in the context of Zotral?

A: A contraindication is a critical safety warning indicating a specific situation or pre-existing condition where the medicine must not be used because the potential risk is considered unacceptably high. For Zotral, this refers to absolute prohibitions, such as combining it with certain other medications like MAOIs, as defined by regulatory bodies.

Q: What are the reported effects of Zotral on liver function?

A: Official clinical studies have reported that Zotral use has been associated with temporary, asymptomatic elevations in serum aminotransferase levels (liver enzymes). Rare instances of clinically apparent acute liver injury have also been reported. These reports underscore the relevance of the patient's medical history, particularly pre-existing liver conditions, as described in the official safety summaries.

Q: Does Zotral have any known interactions with herbal products or vitamins?

A: Regulatory documents explicitly state that Zotral should not be taken with the herbal remedy St. John's Wort due to the increased risk of certain side effects. Official documents describe the need for a healthcare provider to be aware of all concurrent use of herbal remedies, supplements, and vitamins.

Q: Does Zotral require a special prescription or monitoring program?

A: Zotral is a prescription-only medicine. While it is not part of a specialized restricted access program (like REMS), the official warnings emphasize that patients in certain groups, such as children, adolescents, and young adults, require close monitoring for specific severe side effects.

Q: What is the definition of a 'serious' side effect for Zotral according to official documents?

A: Official documents define serious side effects as those that may be life-threatening or require immediate medical attention. For Zotral, these include symptoms of Serotonin Syndrome, Abnormal Bleeding/Hemorrhage, and new or worsening Suicidal Thoughts and Behaviors, which are clearly detailed in the safety section.

Q: What research exists about Zotral's effect on mood regulation?

A: Official efficacy studies and research summaries have demonstrated that Zotral supports the management of conditions related to mood and emotional regulation. Research has indicated that symptomatic changes, such as a reduction in feelings of worry or low mood, may become apparent within a few weeks of beginning treatment.

Q: Can Zotral cause weight gain or weight loss, and how common is it?

A: Official adverse reaction data shows that both weight gain (in adults with long-term use) and decreased weight (weight loss, observed in pediatric studies) have been reported. These are listed as individual adverse reactions, and their occurrence and frequency are noted in regulatory data.

Q: Are there any long-term side effects that have been studied for Zotral?

A: Official patient guidance notes that while most common side effects often lessen after the first few weeks as the body adjusts, some specific adverse effects may persist or last longer. Sexual dysfunction is noted in official labeling as one example of an adverse effect that may continue with prolonged use.

Q: Is Zotral associated with any warnings about driving or operating machinery?

A: Yes, official patient information explicitly cautions that driving a car or operating heavy machinery should be avoided until the medicine’s full effect is established, due to the potential for side effects like dizziness and drowsiness.

Q: Is Zotral available as a generic version?

A: Yes, Zotral contains the active ingredient sertraline hydrochloride, and the FDA has approved generic versions of this compound. These generic alternatives are widely available in both tablet and oral concentrate formulations.

How should Zotral be stored and disposed of?

Zotral (sertraline hydrochloride) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure safety.

Official Storage Conditions

The tablets are required to be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The medicine must be kept in the original container, which must be tightly closed, to protect the product from moisture.

Child-Safety and Disposal

It is a mandatory labeling instruction to keep Zotral out of the sight and reach of children.

For disposal of unused or expired product, official guidance recommends utilizing drug take-back programs. If this is not an option, the tablets should be mixed with an undesirable substance, sealed in a container, and disposed of in the household trash. The medicine should not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zotral found in:

A-Z Index: